Impact BioMedical Inc. Introduces Leadership Team to Drive Innovation and Growth
Impact BioMedical Inc. (NYSE American: IBO) has unveiled its executive leadership team to spearhead the company's next phase of innovation and growth. The team includes:
Frank D. Heuszel as CEO, bringing experience in executive leadership, finance, and strategic planning. He previously served as CEO of DSS, Inc. and has a background in commercial banking.
Mark Suseck as COO, with experience in public and private healthcare companies. He previously served as COO of DSS BioHealth Holdings Inc. and CEO of Vivacitas Oncology Inc.
Todd Macko as CFO, also serving as CFO of DSS Inc. He brings over 25 years of public and corporate fiscal management experience.
The leadership team aims to advance Impact BioMedical's mission of discovering, developing, and patenting unique healthcare solutions.
Impact BioMedical Inc. (NYSE American: IBO) ha svelato il suo team dirigenziale per guidare la prossima fase di innovazione e crescita dell'azienda. Il team include:
Frank D. Heuszel come CEO, portando con sé esperienza nella leadership esecutiva, finanza e pianificazione strategica. In precedenza, ha ricoperto il ruolo di CEO di DSS, Inc. e ha un background nel settore bancario commerciale.
Mark Suseck come COO, con esperienza in aziende di assistenza sanitaria pubbliche e private. In precedenza, ha ricoperto il ruolo di COO di DSS BioHealth Holdings Inc. e CEO di Vivacitas Oncology Inc.
Todd Macko come CFO, ricoprendo anche il ruolo di CFO di DSS Inc. Porta con sé oltre 25 anni di esperienza nella gestione fiscale pubblica e aziendale.
Il team dirigenziale mira a promuovere la missione di Impact BioMedical di scoprire, sviluppare e brevettare soluzioni sanitarie uniche.
Impact BioMedical Inc. (NYSE American: IBO) ha presentado su equipo de liderazgo ejecutivo para liderar la próxima fase de innovación y crecimiento de la empresa. El equipo incluye:
Frank D. Heuszel como CEO, aportando experiencia en liderazgo ejecutivo, finanzas y planificación estratégica. Anteriormente, fue CEO de DSS, Inc. y tiene experiencia en banca comercial.
Mark Suseck como COO, con experiencia en empresas de atención médica públicas y privadas. Anteriormente, fue COO de DSS BioHealth Holdings Inc. y CEO de Vivacitas Oncology Inc.
Todd Macko como CFO, también desempeñándose como CFO de DSS Inc. Aporta más de 25 años de experiencia en gestión fiscal pública y corporativa.
El equipo de liderazgo tiene como objetivo avanzar en la misión de Impact BioMedical de descubrir, desarrollar y patentar soluciones de salud únicas.
Impact BioMedical Inc. (NYSE American: IBO)는 회사의 다음 혁신 및 성장 단계를 이끌기 위해 경영 리더십 팀을 공개했습니다. 팀에는:
Frank D. Heuszel이 CEO로 임명되어, 경영 리더십, 재무 및 전략 계획에 대한 경험을 제공합니다. 그는 이전에 DSS, Inc.의 CEO를 역임했으며, 상업 은행 경력이 있습니다.
Mark Suseck이 COO로, 공공 및 민간 의료 기업에서의 경험을 가지고 있습니다. 그는 이전에 DSS BioHealth Holdings Inc.의 COO와 Vivacitas Oncology Inc.의 CEO를 역임했습니다.
Todd Macko가 CFO로, DSS Inc.의 CFO 직무도 수행합니다. 그는 25년 이상의 공공 및 기업 재무 관리 경험을 가지고 있습니다.
리더십 팀은 Impact BioMedical의 독창적인 의료 솔루션을 발견하고, 개발하고, 특허를 부여하는 사명을 발전시키기 위해 노력하고 있습니다.
Impact BioMedical Inc. (NYSE American: IBO) a dévoilé son équipe de direction pour conduire la prochaine phase d'innovation et de croissance de l'entreprise. L'équipe comprend :
Frank D. Heuszel en tant que PDG, apportant son expérience en leadership exécutif, finances et planification stratégique. Il a précédemment été PDG de DSS, Inc. et possède une expérience dans le secteur bancaire commercial.
Mark Suseck en tant que COO, avec une expérience dans les entreprises de santé publiques et privées. Il a précédemment été COO de DSS BioHealth Holdings Inc. et PDG de Vivacitas Oncology Inc.
Todd Macko en tant que CFO, occupant également le poste de CFO de DSS Inc. Il apporte plus de 25 ans d'expérience dans la gestion financière publique et d'entreprise.
L'équipe de direction vise à faire avancer la mission d'Impact BioMedical de découvrir, développer et breveter des solutions de santé uniques.
Impact BioMedical Inc. (NYSE American: IBO) hat sein Führungsteam vorgestellt, um die nächste Phase der Innovation und des Wachstums des Unternehmens zu leiten. Das Team umfasst:
Frank D. Heuszel als CEO, der Erfahrung in der Unternehmensführung, Finanzen und strategischer Planung mitbringt. Zuvor war er CEO von DSS, Inc. und hat einen Hintergrund im kommerziellen Bankwesen.
Mark Suseck als COO, mit Erfahrung in öffentlichen und privaten Gesundheitsunternehmen. Zuvor war er COO von DSS BioHealth Holdings Inc. und CEO von Vivacitas Oncology Inc.
Todd Macko als CFO, der auch als CFO von DSS Inc. tätig ist. Er bringt über 25 Jahre Erfahrung im öffentlichen und unternehmerischen Finanzmanagement mit.
Das Führungsteam hat sich zum Ziel gesetzt, die Mission von Impact BioMedical voranzutreiben, einzigartige Gesundheitslösungen zu entdecken, zu entwickeln und zu patentieren.
- Experienced leadership team with diverse backgrounds in healthcare, finance, and strategic planning
- CEO Frank D. Heuszel brings executive leadership and commercial banking experience
- COO Mark Suseck has experience in healthcare company operations and strategy
- CFO Todd Macko brings 25 years of public and corporate fiscal management experience
- None.
NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting unique healthcare solutions, is pleased to introduce its executive leadership team, poised to lead the company through its next phase of innovation and growth.
“We are excited to introduce our exceptional leadership team, which brings together a wealth of experience and a shared vision for driving innovation and growth at Impact BioMedical,” said Jason Grady, Impact Biomedical’s Director, and Interim CEO of DSS, Inc. “With their expertise and commitment, we are confident in our ability to advance our mission and deliver impactful healthcare solutions.”
Frank D. Heuszel, Chief Executive Officer (CEO)
Frank D. Heuszel brings experience in executive leadership, finance, and strategic planning to Impact BioMedical. Prior to joining DSS, Inc. as CEO in 2019, he had a successful career in commercial banking, serving in senior executive roles with major US and international banking organizations. His visionary leadership and commitment to excellence position Impact BioMedical for continued success in the healthcare industry. Mr. Heuszel holds an undergraduate degree in Business Administration from The University of Texas at Austin and a J.D. degree from The South Texas College of Law, Houston.
Mark Suseck, Chief Operating Officer (COO)
Mark Suseck, an accomplished leader with experience in public and private healthcare companies, serves as the Chief Operating Officer. Mr. Suseck has been with Impact BioMedical since August 2023 and previously served as the chief operating officer of DSS BioHealth Holdings Inc., where he led company strategy, operations, licensing, acquisitions, and commercialization. He also served as the CEO of Vivacitas Oncology Inc., leading strategy, clinical development, operations, and financing. Mr. Suseck received his undergraduate degree in economics from Rutgers University, with minors in education and philosophy. He completed the Executive Management Program in residence at the University of Michigan Business School.
Todd Macko, Chief Financial Officer (CFO)
Todd Macko, a seasoned financial executive, joins Impact BioMedical as the Chief Financial Officer, while continuing to serve as CFO of DSS Inc. Mr. Macko has been with DSS since January 2021, initially serving as Secretary and Treasurer, and became CFO in May 2023. Mr. Macko brings over 25 years of public and corporate fiscal management experience, with strengths in financial planning and analysis, business process re-engineering, and mergers and acquisitions. Mr. Macko obtained his Bachelor of Science degree in Accounting from Rochester Institute of Technology.
“We are thrilled to have such a talented and experienced leadership team guiding Impact BioMedical,” said Frank D. Heuszel, CEO of Impact BioMedical. “Each member of our executive team brings unique skills and a shared commitment to our mission of developing innovative healthcare solutions. Together, we are well-positioned to drive the company’s growth and deliver impactful results for our stakeholders.”
About Impact BioMedical, Inc.:
Impact BioMedical Inc. (“IBO”) discovers, confirms, and patents unique science and technologies resulting in new offerings in human healthcare and wellness. IBIO works closely with licensing, co-development, joint ventures, and other relationships to bring these offerings to market. For more information, visit Impact BioMedical, Inc.
About DSS, Inc.:
DSS is a multinational company operating businesses within four diversified market sectors. For more information on DSS, visit DSS World.
Safe Harbor Disclosure:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.
Media Contact:
Emily Martin
Email: emartin@impactbiomedinc.com
Investor Relations:
info@impactbiomedinc.com
FAQ
Who are the new executive leaders of Impact BioMedical Inc. (IBO)?
What is Frank D. Heuszel's background before joining Impact BioMedical Inc. (IBO)?
What is Mark Suseck's previous experience before becoming COO of Impact BioMedical Inc. (IBO)?
What is Todd Macko's role at Impact BioMedical Inc. (IBO) and his prior experience?
